Shifeng Mao

1.0k total citations
37 papers, 705 citations indexed

About

Shifeng Mao is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Shifeng Mao has authored 37 papers receiving a total of 705 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Shifeng Mao's work include Renal cell carcinoma treatment (9 papers), Bladder and Urothelial Cancer Treatments (8 papers) and Prostate Cancer Treatment and Research (8 papers). Shifeng Mao is often cited by papers focused on Renal cell carcinoma treatment (9 papers), Bladder and Urothelial Cancer Treatments (8 papers) and Prostate Cancer Treatment and Research (8 papers). Shifeng Mao collaborates with scholars based in United States, Poland and Canada. Shifeng Mao's co-authors include Stephen D. Nimer, Yasushi Miyazaki, Jin Zhang, Richard C. Frank, Cyrus V. Hedvat, Rakesh Goorha, Antonio Di Cristofano, Pier Paolo Pandolfi, Carlos Cordon‐Cardo and H. Daniel Lacorazza and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Immunity.

In The Last Decade

Shifeng Mao

33 papers receiving 698 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shifeng Mao United States 13 398 208 174 150 96 37 705
Anna E. Koopmans Netherlands 11 261 0.7× 219 1.1× 281 1.6× 72 0.5× 111 1.2× 15 805
Margherita Ghisi Australia 9 453 1.1× 105 0.5× 217 1.2× 116 0.8× 36 0.4× 11 663
Susan V. Outram United Kingdom 20 761 1.9× 283 1.4× 164 0.9× 70 0.5× 44 0.5× 26 1.0k
Cyril Šálek Czechia 14 243 0.6× 311 1.5× 275 1.6× 201 1.3× 41 0.4× 47 728
Hisao Nagoshi Japan 12 299 0.8× 146 0.7× 136 0.8× 149 1.0× 22 0.2× 38 520
Alya Zriwil Sweden 8 209 0.5× 302 1.5× 61 0.4× 129 0.9× 19 0.2× 9 518
Akihito Fujimi Japan 9 213 0.5× 152 0.7× 275 1.6× 424 2.8× 39 0.4× 41 739
Tim Ripperger Germany 15 341 0.9× 61 0.3× 135 0.8× 125 0.8× 63 0.7× 46 756
Lucia Liguori Italy 14 278 0.7× 113 0.5× 227 1.3× 32 0.2× 95 1.0× 26 626
Floortje L. Kessler Netherlands 11 214 0.5× 158 0.8× 120 0.7× 168 1.1× 17 0.2× 19 512

Countries citing papers authored by Shifeng Mao

Since Specialization
Citations

This map shows the geographic impact of Shifeng Mao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shifeng Mao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shifeng Mao more than expected).

Fields of papers citing papers by Shifeng Mao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shifeng Mao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shifeng Mao. The network helps show where Shifeng Mao may publish in the future.

Co-authorship network of co-authors of Shifeng Mao

This figure shows the co-authorship network connecting the top 25 collaborators of Shifeng Mao. A scholar is included among the top collaborators of Shifeng Mao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shifeng Mao. Shifeng Mao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Marshall, Catherine H., Benjamin A. Teply, Su Jin Lim, et al.. (2023). Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.. Journal of Clinical Oncology. 41(16_suppl). 5087–5087. 4 indexed citations
3.
Mao, Shifeng, Arash Samiei, Yue Yin, et al.. (2023). Evolving Landscape of Practice Patterns in the Management of Localized Low-Risk Prostate Cancer: A NCDB Study. JU Open Plus. 1(2). 1 indexed citations
4.
Shah, Neil J., Matthew T. Campbell, Shifeng Mao, et al.. (2023). A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology. 41(6_suppl). 666–666. 2 indexed citations
5.
Shah, Neil J., Nicholas J. Vogelzang, Shifeng Mao, et al.. (2022). A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell (ccRCC) carcinoma who have received front-line treatment (NCT04300140).. Journal of Clinical Oncology. 40(16_suppl). 4511–4511. 9 indexed citations
6.
Jayakrishnan, Thejus, et al.. (2021). Desmoplastic Small Round-cell Tumor: Retrospective Review of Institutional Data and Literature Review. Anticancer Research. 41(8). 3859–3866. 11 indexed citations
7.
Benkhadra, Raed, Tarek Nayfeh, Larry J. Prokop, et al.. (2021). Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer. Bladder Cancer. 8(1). 5–17. 3 indexed citations
8.
9.
Samiei, Arash, Ángela Sanguino, Ralph Miller, et al.. (2019). The clinical outcome of renal cell carcinoma with rhabdoid and sarcomatoid differentiation.. Journal of Clinical Oncology. 37(15_suppl). e16083–e16083. 2 indexed citations
10.
Wegner, Rodney E., et al.. (2019). Utilization of Stereotactic Ablative Body Radiation Therapy for Intact Renal Cell Carcinoma: Trends in Treatment and Predictors of Outcome. Advances in Radiation Oncology. 5(1). 85–91. 9 indexed citations
11.
Sanguino, Ángela, Arash Samiei, Ralph Miller, et al.. (2019). Programmed death-ligand 1 (PD-L1) expression in small cell carcinoma of bladder.. Journal of Clinical Oncology. 37(15_suppl). e16019–e16019.
12.
Tang, Amy, et al.. (2018). Bleomycin-induced pulmonary toxicity: A retrospective review of incidence and risk factors.. Journal of Clinical Oncology. 36(15_suppl). e16532–e16532. 1 indexed citations
13.
Ooki, Akira, Maria Del Carmen Rodriguez Peña, Luigi Marchionni, et al.. (2017). YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells. Cancer Research. 78(1). 168–181. 85 indexed citations
14.
Deftereos, Georgios, et al.. (2014). Benign schwannoma masquerading as a malignant metastatic lesion in a patient with renal cell carcinoma.. PubMed. 7(3-4). 123–5. 1 indexed citations
15.
Mao, Shifeng, Danai Daliani, Xuemei Wang, et al.. (2007). Employing the treatment‐free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. The Prostate. 67(15). 1677–1685. 3 indexed citations
16.
Liu, Yan, Cyrus V. Hedvat, Shifeng Mao, et al.. (2006). The ETS Protein MEF Is Regulated by Phosphorylation-Dependent Proteolysis via the Protein-Ubiquitin Ligase SCFSkp2. Molecular and Cellular Biology. 26(8). 3114–3123. 33 indexed citations
17.
Lacorazza, H. Daniel, Yasushi Miyazaki, Antonio Di Cristofano, et al.. (2002). The ETS Protein MEF Plays a Critical Role in Perforin Gene Expression and the Development of Natural Killer and NK-T Cells. Immunity. 17(4). 437–449. 162 indexed citations
18.
Jakubowiak, Andrzej, Célio Pouponnot, Francisco J. Berguido, et al.. (2000). Inhibition of the Transforming Growth Factor β1 Signaling Pathway by the AML1/ETO Leukemia-associated Fusion Protein. Journal of Biological Chemistry. 275(51). 40282–40287. 74 indexed citations
19.
Mao, Shifeng, Richard C. Frank, Jin Zhang, Yasushi Miyazaki, & Stephen D. Nimer. (1999). Functional and Physical Interactions between AML1 Proteins and an ETS Protein, MEF: Implications for the Pathogenesis of t(8;21)-Positive Leukemias. Molecular and Cellular Biology. 19(5). 3635–3644. 112 indexed citations
20.
Mao, Shifeng, Geoffrey Neale, & Rakesh Goorha. (1997). T-cell oncogene rhombotin-2 interacts with retinoblastoma-binding protein 2. Oncogene. 14(13). 1531–1539. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna E. Koopmans Breakdown of academic impact, for papers by Margherita Ghisi Breakdown of academic impact, for papers by Susan V. Outram Breakdown of academic impact, for papers by Cyril Šálek Breakdown of academic impact, for papers by Hisao Nagoshi Breakdown of academic impact, for papers by Alya Zriwil Breakdown of academic impact, for papers by Akihito Fujimi Breakdown of academic impact, for papers by Tim Ripperger Breakdown of academic impact, for papers by Lucia Liguori Breakdown of academic impact, for papers by Floortje L. Kessler
Rankless by CCL
2026